This study was supported by grants from the Hainan Province Science and Technology Special Fund (ZDYF2025LCLH012), the National Key R&D Program of China (2023YFC2306800), the Key Research and Development Project of Zhejiang Province (2024C03149 and 2023C03046), the National Natural Science Foundation of China (82470690 and 92159202), the Fundamental Research Funds for the Central Universities (2025ZFJH03)
Dosing concerns with compounded semaglutide and tirzepatide FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products
In contrast to invasive surgeries, stem cell therapy involves no cuts, has little downtime, and provides a natural-looking pattern of regrowth
Insulin resistance, cardiovascular stiffening and cardiovascular disease
Nakahata, Y., Sahar, S., Astarita, G., Kaluzova, M